AbbVie (NYSE:ABBV), a global, research-driven biopharmaceutical company, has reported its financial results for the year ended 31 December 2019, it was reported on Friday.
The company reported worldwide net revenues at USD33.266bn for the year ended 31 December 2019, up 1.6% on a reported basis, or 2.7% operationally compared to the year-ago period.
The firm posted net earnings of USD7.882bn or USD5.28 diluted earnings per share for the year ended 31 December 2019, compared with earnings of USD5.687bn or USD3.66 diluted earnings per share for the previous year.
'Our strong performance this quarter completes another excellent year for AbbVie,' said Richard A Gonzalez, chairman and chief executive officer, AbbVie. 'The launches of Skyrizi and Rinvoq are going extremely well, and we are entering 2020 with substantial momentum. We also look forward to completing the planned Allergan acquisition in the first quarter.'
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development